Cash expenses rose by 6% due to stock-based compensation and sales/marketing investments. Uncertainty remains on designated entity spectrum approval timeline. Free cash flow guidance is pending transaction close, with anticipation of excess cash. Debt exchange impact on purchase price is uncertain.